Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04251351
Other study ID # H19-03570
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 13, 2021
Est. completion date November 1, 2025

Study information

Verified date June 2023
Source University of British Columbia
Contact Katherine Plewes, Dr.
Phone +1-604-603-4033
Email katherine@tropmedres.ac
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomised open labeled, parallel-group, controlled trial to assess the efficacy of paracetamol to reduce kidney dysfunction caused by cell-free haemoglobin-mediated oxidative damage in paediatric patients with falciparum malaria complicated by intravascular haemolysis.


Description:

Kidney dysfunction is an independent predictor of mortality in both adults and children with severe malaria. In the largest studies of paediatric severe malaria, approximately 25% of children had kidney dysfunction and these patients accounted for roughly 50% of total deaths. Although the multifactorial mechanism of severe malaria-associated AKI has primarily been studied in adults, evidence suggests that similar mechanisms of renal injury are involved in paediatric severe malaria. Cell-free haemoglobin (CFH) -mediated oxidative damage has recently been recognized as an important pathway in a range of common conditions, including rhabdomyolysis, primary pulmonary graft dysfunction, and haemolytic disorders, such as post-cardiac surgery, and malaria. During malaria infection, there is haemolysis of parasitized and uninfected red blood cells (RBCs). CFH-mediated lipid peroxidation generates F2-isoprostanes (F2-IsoPs) and isofurans (IsoFs), which are considered robust in vivo measures of oxidative stress. F2-IsoPs are potent renal vasoconstrictors that act via thromboxane A2 receptors. Both F2-IsoPs and IsoFs have been associated with AKI in patients with rhabdomyolysis, sepsis, adults with severe malaria and haemolysis post-cardiopulmonary bypass (CPB). Further, elevated haemin and CFH concentrations were associated with mortality. In a cohort of children with severe malaria, elevated haem-to-haemopexin ratio was associated with stage 3 AKI, and 6-month mortality. These studies demonstrate that intravascular haemolysis occurs with increasing severity in paediatric malaria. Haem redox cycling between ferric (Fe3+) and ferryl (Fe4+) states generates globin radicals, inducing lipid peroxidation. These data suggested that haemolysis induces oxidative damage, and CFH-mediated oxidative damage contributes to AKI complicating paediatric malaria. A novel mechanism of paracetamol was recently demonstrated, showing that paracetamol acts as a potent inhibitor of haemoprotein-catalyzed lipid peroxidation, by reducing ferryl haem to its less toxic ferric state and quenching globin radicals. We hypothesize that this novel inhibitory mechanism of paracetamol may provide renal protection in children with severe malaria by reducing the haemoprotein-induced lipid peroxidation. As there is currently no consensus that exists concerning adequate medical treatment for severe malaria complicated by intravascular haemolysis and AKI, the potential application of this safe and extensively used drug would be of great benefit. The study will be a randomised, open-labelled, controlled trial. Randomisation will be stratified into two groups : (i) Patients with no acute kidney injury (AKI) at enrolment, and (ii) Patients with AKI at enrolment. Both groups will be randomised into two arms: Arm 1: Paracetamol 15 mg/kg/dose 6 hourly for 72 hours Arm 2: Mechanical antipyresis if fever in the first 72 hours. All patients will receive intravenous artesunate followed by artemether-lumefantrine as soon as they are able to take oral medication or according to medical judgment. The study will be conducted at the Kinshasa Medical Oxford Research Unit (KIMORU, Democratic Republic of the Congo, DRC). The recruitment phase of the study is expected to last 18 months, from September 2021 - February 2022. The total time to complete the study will be approximately 3 years. Funder: Canadian Institutes of Health Research CIHR grant reference number : PJT-162116 UBC grant number: 20R01487


Recruitment information / eligibility

Status Recruiting
Enrollment 460
Est. completion date November 1, 2025
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year to 14 Years
Eligibility Inclusion Criteria: 1. Male or Female, patients aged 1 to = 14 years 2. Severe P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum or positive PfHRP2 rapid diagnostic test (RDT). Pre-specified modified criteria for severe falciparum malaria Upon hospital admission, asexual parasitaemia plus at least ONE of the following: - Glasgow coma score < 11/15 or Blantyre coma score <3/5 in pre-verbal children - Generalized convulsions (=2 in 24 hours) - Jaundice (visible jaundice) - Severe anaemia (HCT <15%/Hb<5 g/dL: aged <12) Severe anaemia (HCT <20%/Hb<7 g/dL: aged =12) - Hyperparasitaemia (>10%) - Hypoglycaemia (glucose < 2.2 mmol/L; <40 mg/dL) - Kidney dysfunction (blood urea > 20 mmol/L) - Acidosis (venous bicarbonate <15 mmol/L or base excess less than -3.3mEq/L) - Venous lactate > 5 mmol/L - Shock (systolic blood pressure < 70 mmHg (<12 years) <80 mmHg (=12 years) with cool extremities or capillary refill >3 seconds) - Respiratory distress (costal indrawing, use of accessory muscles, nasal flaring, deep breathing or severe tachypnea (respiratory rate>ULN for age) - Spontaneous bleeding - Prostration (inability to set upright, or drink)* Abbreviations: HCT, haematocrit; Hb, haemoglobin; *cannot be only severity criteria 3. Temperature >38°C on admission or fever during the preceding 48 hours. 4. Less than 24 hours of antimalarial therapy 5. Attending caregiver of participant willing and able to give informed consent for participation in the study Exclusion Criteria: The participant may not enter the trial if ANY of the following apply: 1. Contraindication or known allergy to paracetamol 2. Known chronic liver disease or tender hepatomegaly 3. Known chronic kidney disease, history of renal replacement therapy or renal biopsy 4. Participants who are already enrolled in another research trial involving an investigational product or have participated to the same study before

Study Design


Intervention

Drug:
Paracetamol
Paracetamol 15 mg/kg/dose IV 6 hourly for 72 hours
Procedure:
Mechanical antipyresis
Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours. If a temperature >38.5°C persists despite mechanical antipyresis, or if deemed necessary by the treating clinician, then paracetamol can be administered according to local practice (paracetamol IV 15 mg/kg as needed).

Locations

Country Name City State
Congo, The Democratic Republic of the The Kinshasa Medical Oxford Research Unit (KIMORU) Kinshasa Congo

Sponsors (3)

Lead Sponsor Collaborator
University of British Columbia Kinshasa Medical Oxford Research Unit, Mahidol Oxford Tropical Medicine Research Unit

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute kidney injury (AKI) or death among patients enrolled without AKI (Composite outcome) Composite outcome of development of AKI (defined as creatinine =26.5 µmol/L or =1.5x baseline), or death at any timepoint during first 7 days of enrolment
Primary Acute kidney injury (AKI) progression or death among patients enrolled with AKI (Composite outcome) Composite outcome of worsening of AKI (defined as creatinine =2x baseline, or =3x baseline, or initiation of RRT or eGFR <35 ml/min/ 1.73 m2) or death at any timepoint. during first 7 days of enrolment
Secondary Number of patients with serious adverse events Number of patients with serious adverse events (mortality and/or hepatotoxicity, as defined by Hy's Law). AST/ALT/total bilirubin during the first 5 days from enrolment; mortality assessed Day 0 to 7.
Secondary Proportion of patients who develop Major Adverse Kidney Events (MAKE) composite Major Adverse Kidney Events (MAKE) composite, defined as = 1 efficacy renal endpoints: (i) death, (ii) need for renal replacement therapy, (iii)= 50% reduction in eGFR from baseline to 90 days. 90 days
Secondary Fever clearance time Time taken for aural temperature: (i) to fall < 37.5°C (FCT-A), and (ii) to fall < 37.5°C and remain there for >24 h (FCT-B) 6-hourly temperature assessments during first 7 days from enrolment
Secondary Coma recovery Time until Glasgow Coma Score (GCS) return to 15 (or Blantyre Coma Score (BCS) return to 5 in preverbal children) 6-hourly GCS/BCS assessments during first 7 days from enrolment
Secondary Longitudinal change in renal function As measured by creatinine concentration (umol/L) During the first 7 days from enrolment
Secondary Longitudinal change in markers of hemolysis As measured by cell-free haemoglobin (ug/mL), haemopexin (ug/mL), haptoglobin (ug/mL), haem (uM), F2-isoprostane (pg/mL) and isofurans (pg/mL) concentrations during the first 3 days from enrolment
Secondary Longitudinal change of endothelial activation As measured by concentrations of angiopoietin-Tie2 pathway markers (i.e. Ang-1, Ang-2, sTie2, sTie1) during the first 3 days from enrolment
Secondary Longitudinal change of immune activation As measured by soluble triggering receptor expressed on myeloid cells concentration (sTREM-1; pg/mL) during the first 3 days from enrolment
Secondary Longitudinal change of AKI biomarker As measured by cystatin-C concentration (Cys-C; ug/mL) during the first 3 days from enrolment
Secondary Parasite (parasites/ul) clearance as measured by time until two consecutive negative smears (hours), and by rate using the parasite clearance estimator to determine slope half-life (hours) from 12-hourly parasite counts. 12-hourly parasitemia assessments during first 7 days from enrolment
Secondary Exploratory analysis with sex Primary efficacy analyses will be analysed using a logistic regression model to obtain odds ratios, comparing the odds of a combined endpoint of kidney function deterioration or death between treatment groups. A multivariable model including an interaction term (sex and treatment) will be assessed in the primary analyses to explore potential differences between males and females. During first 7 days from enrolment
Secondary Pharmacokinetic properties Population pharmacokinetic model (relative bioavailability, mean transit absorption time (hours), apparent oral elimination clearance (L/hours), apparent volume of distribution (L) during the first 24 hours from enrolment
Secondary Pharmacokinetic properties Peak plasma concentration (Cmax; mg/L) during the first 24 hours from enrolment
Secondary Pharmacokinetic properties Time to peak plasma concentration (Tmax; hours) during the first 24 hours from enrolment
Secondary Pharmacokinetic properties Terminal elimination (t1/2; hours) during the first 24 hours from enrolment
Secondary Pharmacokinetic properties Area under the plasma drug concentration-time curve (AUC0-24; mg×h×L-1) during the first 24 hours from enrolment
Secondary Pharmacodynamic relationships Pharmacodynamic effects on creatinine concentration (mol/L) during first 7 days from enrolment
Secondary Pharmacodynamic relationships Pharmacodynamic effects on liver toxicity, as measured by AST and ALT (U/L) during first 7 days from enrolment
Secondary Pharmacodynamic relationships Pharmacodynamic effects on temperature (Celsius) during first 7 days from enrolment
Secondary Pharmacodynamic relationships Pharmacodynamic effects on parasitemia, as measured by parasites/ul and slope half-life during first 7 days from enrolment
Secondary Pharmacodynamic relationships Pharmacodynamic effects on GCS (or BCS in pre-verbal children) during first 7 days from enrolment
See also
  Status Clinical Trial Phase
Recruiting NCT05538351 - A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03938038 - Guidance of Ultrasound in Intensive Care to Direct Euvolemia N/A
Recruiting NCT05805709 - A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial N/A
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT05897840 - Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients N/A
Recruiting NCT04986137 - Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT04095143 - Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
Not yet recruiting NCT06026592 - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Not yet recruiting NCT06064305 - Transcriptional and Proteomic Analysis of Acute Kidney Injury
Terminated NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Terminated NCT03305549 - Recovery After Dialysis-Requiring Acute Kidney Injury N/A
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Terminated NCT02860130 - Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Phase 3
Completed NCT06000098 - Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
Not yet recruiting NCT05548725 - Relation Between Acute Kidney Injury and Mineral Bone Disease
Completed NCT02665377 - Prevention of Akute Kidney Injury, Hearttransplant, ANP Phase 3
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A